FormsNet3 - Blank Form


 

 
Sequence Number:    

 

 
Date Received: __ __ __ __ - __ __- __ __  

 

 
CIBMTR Center Number:    

 

 
CIBMTR Recipient ID:    

 

 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

HCT Type (check all that apply): 

 

 

gfedcb
Autologous

 

 

gfedcb
Allogeneic, unrelated

 

 

gfedcb
Allogeneic, related

Product Type: (check all that apply) 

 

 

gfedcb
Bone marrow

 

 

gfedcb
PBSC

 

 

gfedcb
Single cord blood unit

 

 

gfedcb
Multiple cord blood units

 

 

gfedcb
Other product

 

 
Specify:    

 

 
Is this the report of a second or subsequent transplant for the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 

 
Is the second or subsequent transplant for relapse or progression of the same disease?

  
 nmlkji

yes  
 nmlkji

no  

 

 
1  What is the diagnosis?

    
 nmlkji

Lymphoplasmacytic lymphoma  (LPL) 

 nmlkji
Waldenström’s macroglobulinemia  (MAC) 

 

 
2  What was the date of diagnosis? __ __ __ __ - __ __- __ __  

 

 
3  Was peripheral neuropathy present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
4  Did the recipient have known nodal involvement?

    
 nmlkji

yes  
 nmlkji

no  

 

 
5  Specify the size of the largest nodal mass:    cm  X 

 

 
   cm 

 

 
6  Was there any known extranodal or splenic involvement?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Subsequent Transplant 

  Disease Assessment at Diagnosis Questions: 1 - 2

  Clinical Features at Diagnosis Questions: 3 - 23

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 1 / 10



Specify the site(s) of involvement: 

 

 
7  Bone

    
 nmlkji

yes  
 nmlkji

no  

 

 
8  Gastrointestinal (GI) tract

    
 nmlkji

yes  
 nmlkji

no  

 

 
9  Kidney

    
 nmlkji

yes  
 nmlkji

no  

 

 
10  Liver

    
 nmlkji

yes  
 nmlkji

no  

 

 
11  Lung

    
 nmlkji

yes  
 nmlkji

no  

 

 
12  Spleen

    
 nmlkji

yes  
 nmlkji

no  

 

 
13  Other site

    
 nmlkji

yes  
 nmlkji

no  

 

 
14  Specify other site:    

 

 
15  Were systemic symptoms (B symptoms) present?

    (unexplained fever > 38 C; night sweats; or unexplained weight loss > 10% body weight in six months before diagnosis) 

 nmlkji
yes  

 nmlkji
no  

 nmlkji
Unknown  

 

 
16  Was clinical hyperviscosity syndrome present?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

Specify clinical symptoms present at diagnosis: 

 

 
17  Bleeding / bruising

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
18  Dizziness

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
19  Fatigue

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
20  Visual disturbance

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
21  Other

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
22  Specify other symptom:    

 

 
23  Was plasmapheresis or plasma exchange required?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Laboratory Studies at Diagnosis Questions: 24 - 75

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 2 / 10



Report findings prior to any first treatment for LPL or MAC 

 

 
24  Absolute lymphocyte count

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
25     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
26  Hemoglobin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
27     

 

 

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 

 
28  Platelets

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
29     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
30  Bone marrow aspirate (examined for histologic involvement)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 

 
31     % 

 

 
32  Bone marrow biopsy (examined for histiologic involvement)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 

 
33     % 

 

 
34  Specify the type of histological involvement in marrow

    
 nmlkji

lymphoplasmacytoid  
 nmlkji

lymphoplasmacytic  
 nmlkji

polymorphous  
 nmlkji

Unknown  

 

 
35  Was flow cytometry (immunophenotyping) performed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
36  CD5

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
37  CD19

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
38  CD20

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
39  CD22

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
40  CD79

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

 

 
41  Surface IgM

    
 nmlkji

Positive  
 nmlkji

Negative  
 nmlkji

Not Done  

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 3 / 10



 

 
42  Was documentation submitted to the CIBMTR?

    (e.g. flow cytometry (immunophenotype) report) 

 nmlkji
yes  

 nmlkji
no  

 

 
43  Serum β2 microglobulin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
44     

 

 

 nmlkji
μg/dL  

 nmlkji
mg/L  

 nmlkji
nmol/L  

Specify the immunoglobulin M (IgM) protein chains present at diagnosis: 

 

 
45  Serum heavy chain - IgM

    
 nmlkji

yes  
 nmlkji

no  

 

 
46  Urine heavy chain - IgM

    
 nmlkji

yes  
 nmlkji

no  

 

 
47  Serum light chain

    
 nmlkji

kappa  
 nmlkji

lambda  

 

 
48  Urine light chain

    
 nmlkji

kappa  
 nmlkji

lambda  

 

 
49  Relative serum viscosity

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
50     

 

 
51  Upper limit of normal for relative serum viscosity:    

 

 
52  Serum monoclonal protein (M-spike): (only from electrophoresis)

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
53     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
54  Urinary monoclonal protein (M-spike)

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
55     mg / 24 hours 

 

 
56  LDH

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
57     

 

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 

 
58  Upper limit of normal for LDH:    

 

 

 nmlkji
U/L  

 nmlkji
µkat/L  

 

 
59  Cold agglutinins

    
 nmlkji

Positive  (for agglutination in titers at or below 1:16 or IgM antibodies that bind at < 37°C) 

 nmlkji
Negative  

 nmlkji
Unknown  

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 4 / 10



 

 
60  Cryoglobulin

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

Specify the following serum quantitative immunoglobulins (measured prior to any disease treatment): 

 

 
61  IgG

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
62     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
63  Upper limit of normal for IgG:    

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
64  IgA

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
65     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
66  Upper limit of normal for IgA:    

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
67  IgM

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
68     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
69  Upper limit of normal for IgM:    

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
70  Were cytogenetics tested (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
71  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

 

 
72  del(6q) / 6q–

    
 nmlkji

yes  
 nmlkji

no  

 

 
73  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 

 
74  Specify other abnormality:    

 

 
75  Was documentation submitted to the CIBMTR?

    (e.g. cytogenetic or FISH report)  

 nmlkji
yes  

 nmlkji
no  

 

 
76  Was therapy given?

    (including chemotherapy used to mobilize stem cells) 

 nmlkji
yes  

 nmlkji
no  

  Pre-HCT Therapy Questions: 76 - 120

  Line of Therapy (1) Questions: 77 - 120 

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 5 / 10



Line of Therapy: 

 

 
77  Systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
78  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
79  Date started: __ __ __ __ - __ __- __ __  

 

 
80  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
81  Date stopped: __ __ __ __ - __ __- __ __  

 

 
82  Number of cycles

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
83  Number of cycles:    

 

 
84  Alemtuzumab (Campath)

    
 nmlkji

yes  
 nmlkji

no  

 

 
85  Bendamustine

    
 nmlkji

yes  
 nmlkji

no  

 

 
86  Bortezomib (Velcade)

    
 nmlkji

yes  
 nmlkji

no  

 

 
87  Carfilzomib

    
 nmlkji

yes  
 nmlkji

no  

 

 
88  Chlorambucil (Leukeran)

    
 nmlkji

yes  
 nmlkji

no  

 

 
89  Cladribine (2-CdA, Leustatin)

    
 nmlkji

yes  
 nmlkji

no  

 

 
90  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 

 
91  Cyclophosphamide (Cytoxan)

    
 nmlkji

yes  
 nmlkji

no  

 

 
92  Doxorubicin (Adriamycin)

    
 nmlkji

yes  
 nmlkji

no  

 

 
93  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 

 
94  Everolimus (RAD-001)

    
 nmlkji

yes  
 nmlkji

no  

 

 
95  Fludarabine (Fludara)

    
 nmlkji

yes  
 nmlkji

no  

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 6 / 10



 

 
96  Idarubicin (Idamycin)

    
 nmlkji

yes  
 nmlkji

no  

 

 
97  Ifosfamide (Ifex)

    
 nmlkji

yes  
 nmlkji

no  

 

 
98  Lenalidomide (Revlimid)

    
 nmlkji

yes  
 nmlkji

no  

 

 
99  Melphalan (L-PAM, Alkeran)

    
 nmlkji

yes  
 nmlkji

no  

 

 
100  Mitoxantrone

    
 nmlkji

yes  
 nmlkji

no  

 

 
101  Pentostatin (Nipent)

    
 nmlkji

yes  
 nmlkji

no  

 

 
102  Rituximab (Rituxan, MabThera)

    
 nmlkji

yes  
 nmlkji

no  

 

 
103  Temsirolimus (Torisel)

    
 nmlkji

yes  
 nmlkji

no  

 

 
104  Thalidomide (Thalomid)

    
 nmlkji

yes  
 nmlkji

no  

 

 
105  Vincristine (VCR, Oncovin)

    
 nmlkji

yes  
 nmlkji

no  

 

 
106  Other systemic therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
107  Specify other systemic therapy:    

 

 
108  Was this line of therapy given for stem cell mobilization (priming)?

    
 nmlkji

yes  
 nmlkji

no  

 

 
109  Radiation therapy

    
 nmlkji

yes  
 nmlkji

no  

 

 
110  Date therapy started

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
111  Date started: __ __ __ __ - __ __- __ __  

 

 
112  Date therapy stopped

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
113  Date stopped: __ __ __ __ - __ __- __ __  

Specify site(s) of radiation therapy: 

 

 
114     

 

 
115     

 

 
116     

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 7 / 10



 

 
117  Best response to line of therapy:

    
 nmlkji

Complete 

remission (CR)  

- disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy / 

organomegaly (confirmed by CT scan), or signs or symptoms attributable to MAC/LPL. Reconfirmation of the CR status is required at least 6 

weeks apart with a second immunofixation unless disease assessment is less than 6 weeks from HCT.  

 nmlkji
Partial remission 

(PR)  

- at least 50% reduction of serum monoclonal IgM concentration on protein electrophoresis and at least 50% decrease in adenopathy / 

organomegaly on physical examination or on CT scan. No new symptoms or signs of active disease.  

 nmlkji
Minor remission / 

stable disease (MR / 

SD)  

- at least 25% but less than 50% reduction of serum monoclonal IgM by protein electrophoresis. No new symptoms or signs of active 

disease. Or a less-than-25% reduction and less-than-25% increase of serum monoclonal IgM by electrophoresis wihtout progression 

of adenopathy / organomegaly, cytopenias, or clinically significant symptoms due to disease and/or signs of MAC/LPL.  

 nmlkji
Progressive 

disease (PD)  

- at least 25% increase in serum monoclonal IgM by protein electrophoresis confirmed by a second measurement or progression of clinically 

significant findings due to disease (ie, anemia, thrombocytopenia, leukopenia, bulky adenopathy / organomegaly) or symptoms (unexplained 

recurrent fever of at least 38.4°C, drenching night sweats, at least 10% body weight loss, or hyperviscosity, neuropathy, symptomatic 
cryoglobulinemia, or amyloidosis) attributable to MAC/LPL.  

 nmlkji
Not assessed  

 

 
118  Date assessed: __ __ __ __ - __ __- __ __  

 

 
119  Did patient relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

 

 
120  Date of relapse/progression: __ __ __ __ - __ __- __ __  

 

 
121  Absolute lymphocyte count

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
122     

 

 

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 

 
123  Bone marrow aspirate (examined for histologic involvement)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 

 
124     % 

 

 
125  Bone marrow biopsy (examined for histiologic involvement)

    
 nmlkji

Known  
 nmlkji

Unknown  
 nmlkji

Not applicable  

 

 
126     % 

 

 
127  Serum β2 microglobulin

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
128     

 

 

 nmlkji
μg/dL  

 nmlkji
mg/L  

 nmlkji
nmol/L  

 

 
129  Relative serum viscosity

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
130     

 

 
131  Serum monoclonal protein (M-spike): (only from electrophoresis)

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
132     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

  Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen (Conditioning) Questions: 121 - 150

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 8 / 10



 

 
133  Urinary monoclonal protein (M-spike)

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
134     mg / 24 hours 

 

 
135  Cold agglutinins

    
 nmlkji

Positive  (for agglutination in titers at or below 1:16 or IgM antibodies that bind at < 37°C) 

 nmlkji
Negative  

 nmlkji
Unknown  

 

 
136  Cryoglobulin

    
 nmlkji

Present  
 nmlkji

Absent  
 nmlkji

Unknown  

 

 
137  IgG

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
138     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
139  Upper limit of normal for IgG:    

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
140  IgA

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
141     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
142  Upper limit of normal for IgA:    

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
143  IgM

    
 nmlkji

Known  
 nmlkji

Unknown  

 

 
144     

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
145  Upper limit of normal for IgM:    

 

 

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 

 
146  Were cytogenetics tested (conventional or FISH)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

 
147  Results of tests

    
 nmlkji

Abnormalities identified  

 nmlkji
No evaluable metaphases  

 nmlkji
No abnormalities  

 

 
148  del(6q) / 6q–

    
 nmlkji

yes  
 nmlkji

no  

 

 
149  Other abnormality

    
 nmlkji

yes  
 nmlkji

no  

 

 
150  Specify other abnormality:    

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 9 / 10



 

 
151  What was the disease status at the last evaluation prior to the preparative regimen?

    
 nmlkji

Complete 

remission (CR)  

- disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy / 

organomegaly (confirmed by CT scan), or signs or symptoms attributable to MAC/LPL. Reconfirmation of the CR status is required at least 6 weeks 

apart with a second immunofixation unless disease assessment is less than 6 weeks from HCT.  

 nmlkji
Partial remission 

(PR)  

- at least 50% reduction of serum monoclonal IgM concentration on protein electrophoresis and at least 50% decrease in adenopathy / 

organomegaly on physical examination or on CT scan. No new symptoms or signs of active disease.  

 nmlkji
Minor remission / 

stable disease (MR / 

SD)  

- at least 25% but less than 50% reduction of serum monoclonal IgM by protein electrophoresis. No new symptoms or signs of active disease. 

Or a less-than-25% reduction and less-than-25% increase of serum monoclonal IgM by electrophoresis without progression of adenopathy / 

organomegaly, cytopenias, or clinically significant symptoms due to disease and/or signs or MAC/LPL.  

 nmlkji
Progressive 

disease (PD)  

- at least 25% increase in serum monoclonal IgM by protein electrophoresis confirmed by a second measurement or progression of clinically 

significant findings due to disease (ie, anemia, thrombocytopenia, leukepenia, bulky adenopathy / organomegaly) or symptoms (unexplained 

recurrent fever of at least 38.4°C, drenching night sweats, at least 10% body weight loss, or hyperviscosity, neuropathy, symptomatic cryoglobulinemia, 
or amyloidosis) attributable to MAC/LPL.  

 nmlkji
Not assessed  

 

 
152  Date assessed: __ __ __ __ - __ __- __ __  

 

 
First Name:    

 

 
Last Name:    

 

 
E-mail address:    

 

 
Date: __ __ __ __ - __ __- __ __  

  Disease Status at Last Evaluation Prior to the Preparative Regimen (Conditioning) Questions: 151 - 152

Form 2019 R3.0: Waldenström’s Macroglobulinemia/ Lymphoplasmacytic Lymphoma (MAC) Pre-HCT Data  
Center:  CRID: 

            CIBMTR Form 2019 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 10 / 10